Skip to main content

Table 1 Clinical characteristics of patient population

From: Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension

 

All patients (n = 58)

Demographics

 

Age (years)

53 ± 14

Women, n(%)

43 (74%)

Time of PH Diagnosis

 

Prior to CMR study

38 (66%)

After CMR study

20 (34%)

WHO Categorizations

 

WHO Group I

44 (76%)

   Idiopathic PAH

24

   Associated PAH

20

WHO Group II

8 (14%)

WHO Group III

1 (1.7%)

WHO Group IV

2 (3.4%)

WHO Group V

3 (5.2%)

Medications at time of CMR

 

Prostacyclin analogs ± other* PH medications

18 (31%)

Other* PH medications only

18 (31%)

No PH medications

22 (38%)

  1. *Other medications include endothelin receptor antagonists, calcium channel blockers, phosphodiesterase inhibitors, and multikinase inhibitors (sorafenib)